NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center
Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule…
Versameb to present at the BIO Asia-Taiwan Conference
Versameb AG (“Versameb”), a pre-clinical stage company focused…
Vicebio launched by medicxi to advance the Molecular Clamp technology and develop next generation RSV vaccine
Focused on delivering highly effective vaccines against life-threatening…
Doug Kohrs appointed to Sequana Medical Board of Directors
Highly experienced US medtech leader brings more than 40 years’…
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update
DSR (Direct Sodium Removal) heart failure drug development:
…
Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans
FDA clarifies Phase 3 and US registration pathway for XF-73…
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer
Recognition of commendable, longstanding dedication to the…
Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance
MAFTEST® analyses of the NSABP-B34 and AZURE landmark clinical…
Invizius Announces Appointment of Peter Stenvinkel, Professor of Nephrology at Karolinska Institutet, to the Clinical Advisory Board
World leading expert and key opinion leader in nephrology
Glasgow,…
Declaration of conformity drawn up for Inbiomotion MAFTEST®
Barcelona, July 13 2022, On 13 May 2022, the conformity assessment…
Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi
Neuraxpharm, the central nervous system (CNS) specialist, to…
vasopharm GmbH Announces Brain Lactate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury
Ronopterin significantly reduces lactate levels in brain microdialysate…
Ariceum Therapeutics Appoints Chief Business Officer
BERLIN, 7 July 2022 – Ariceum Therapeutics (Ariceum), a private…
DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®
Parsippany, N.J. and Turku, Finland – July 6, 2022 – IVERIC…
Destiny Pharma announces start of a new XF-73 research programme
Destiny Pharma announces start of a new XF-73 research programme
Aim…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
